Dernières informations Corporate et commerciales

Derniers communiqués

Veracyte Completes Acquisition of HalioDx

Fuels growth by enabling IVD test development and manufacturing for nCounter diagnostic platform

Expands scientific...

 Lire la suite

HalioDx and Veracyte set proposed acquisition terms

French version available (pdf)

 Lire la suite

Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program

  • Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil

HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced...

 Lire la suite

Distributors

Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients

HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

New data reinforce Immunoscore® clinical utility in localized Colon Cancer

  • Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...
 Lire la suite

Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center

COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients

HalioDx SAS, the immuno-oncology...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

Mr Gilles Bloch, Président Directeur Général de l’Inserm, remet l’insigne de Chevalier de la Légion d’honneur à Jérôme Galon

HalioDx SAS, la société de diagnostic en immuno-oncologie, a annoncé aujourd'hui que son fondateur scientifique,...

 Lire la suite

See more Press releases